Genedata Biopharma Platform
The Genedata Biopharma Platform is first-in-class enterprise software that automates R&D workflows and drives scientific innovation. It delivers analytics- and AI-driven insights that help bring better life-saving therapies to patients faster and more cost-effectively.
Receive your quote directly from the manufacturer.
All Therapeutic Modalities. Supported.
A central end-to-end digital backbone enables the registration and tracking of both complex biologics and small molecules, integrating analytics and functional assay results into a ‘single source of truth’ across R&D.
Eight Systems. Working Separately or Together.
The Genedata Biopharma Platform is composed of eight systems that can be used together or individually to enable innovation, accelerate R&D workflows, increase R&D efficiency and ultimately improve clinical success.
Increase Bioengineering Output by 10 x
Software Benefits:
- Register all biotherapeutic modalities
- Streamline screening and optimization processes and biological data handling
- Automate data capture and analysis from instruments and robotics
- Drive innovation with a structured data foundation for AI/ML
- Ensure data integrity & traceability
Automating MS-based workflows to accelerate antibody-drug conjugate discovery
This case study describes how Merck streamlined antibody-drug conjugate (ADC) discovery by implementing the Genedata Biopharma Platform to automate mass spectrometry (MS)-based workflows. The solution integrates data from multiple analytical techniques, enabling consistent, real-time access to molecular and analytical information across global research sites.
By centralizing data and automating workflows, the platform eliminates manual data handling and reduces the risk of human error. It enables high-throughput processing of ADC samples, automatic calculation of key attributes such as drug-to-antibody ratio (DAR), and improved traceability across the discovery pipeline. This approach supports faster decision-making, improved data accessibility, and more efficient identification of promising ADC candidates.
Resource details:
- Resource type: Case study
- Page count: 2
- Read time: 3 mins
Mass spec data digital transformation at Lilly Biologics Discovery
Thursday, June 11 at 16:00 BST | 17:00 CEST | 11:00 EDT | 08:00 PDT
Mass spectrometry (MS) now produces richer, more complex datasets than ever, offering biopharmaceutical teams new opportunities to deepen biological insight and accelerate discovery. Unlocking this potential requires transforming raw MS outputs into structured, automated, and analysis‑ready data that can support scalable workflows, reproducible analytics, and AI‑driven prediction models.
In this SelectScience® webinar, learn from Dr. Joomi Ahn, Senior Director at Eli Lilly, as she shares how the Biologic Discovery Mass Spectrometry group implemented Genedata Expressionist to build an integrated digital ecosystem. By connecting electronic lab notebooks, liquid‑handling automation, and custom artificial intelligence and machine‑learning tools, the team achieved 3–10× productivity gains.
By registering for this webinar, you will hear first‑hand how these capabilities now enable high‑throughput intact mass analysis, bispecific assembly checks, and stability peptide mapping. This flexible, vendor‑neutral foundation can help teams accelerate their workflows and unlock insights that drive the next wave of biologic drug discovery.
What will this webinar cover?
- How to standardize MS workflows across sites with a scalable, vendor-neutral, flexible platform
- How to automate end-to-end MS processes to increase productivity, data integrity, and knowledge access
- How to integrate wet and digital labs to shorten developability timelines for any new and hybrid modality
- How to leverage sequence liability prediction and automated stability reporting to accelerate drug candidate selection
Who should attend?
- Analytical scientists and innovation leaders looking for scalable, vendor-neutral ways to standardize and automate MS workflows across labs and sites.
- Developability and CMC characterization stakeholders using MS data and digital platforms to streamline biologics discovery and development, reduce optimization cycles, and accelerate timelines.
- VP/Director-level biopharma leaders building digital foundations in R&D and evaluating how AI and digital tools can accelerate timelines and deliver measurable impact.
- IT, informatics, and scientific software developers integrating legacy systems, enabling scalable infrastructure, and delivering user-friendly tools that strengthen scientific workflows.
Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes. If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
Webinar details
- Cost: Free to attend
- Location: Online
- Duration: 60 minutes
Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on‑demand recording once it becomes available.
